Cannabinoid drug developer Inmed sets sights on partners
By Michael Fitzhugh
Staff Writer
Staff Writer
Friday, April 10, 2015
Inmed Pharmaceuticals Ltd., a Canadian-listed start-up mixing cannabinoids and noncannabis elements for the treatment of glaucoma is working to move into the clinic this year and attract the kind of big pharma backers that have rallied to support cannabinoid drugmaker GW Pharmaceuticals plc.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.